Dengue, a virus endemic to Latin America and Southeast Asia, infects about 400 million people and causes about 25,000 deaths each year by dengue hemorrhagic fever (DHF). To date there is no cure for dengue, and its toll hits hardest in areas with poorly developed medical systems. Due to the deadly consequences of this virus,(...)
FDA
Advancing the Manufacturing of Human Cell and Gene Therapies
Posted by | Events and HappeningsCellular and gene therapy-related research in the United States is growing at a fast pace, with many products moving forward in clinical development. Applications of these cellular and gene therapies range from using a person’s own cells and genetically altering them to fight cancer, to replacing a gene in the eye to restore vision in(...)
Once-Daily Combination Pills Offer More Than Convenience
Posted by | Perspectives in ResearchIn November 2015, the FDA approved the HIV-1 medication Genvoya, a once-daily pill containing fixed doses of the HIV drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. This is the latest once-daily medication to be produced to treat HIV, a disease that used to be managed primarily with many different pills taken multiple times a day.(...)
Legislative Bill Prompts Discussion of Cross-Talk in the Scientific Community
Posted by | Perspectives in ResearchEarlier this month, the U.S. House of Representatives approved a bill directly impacting the biomedical research community. If approved by the Senate, the 21st Century Cures Act promises to increase the budget of the National Institutes of Health (NIH) and provide it with an additional $8.75 billion over the next five years. The Food and(...)